

F1
Contd

i) a compressible filler component combined with a disintegrating component;

Sub G
Contd

ii) 3-20% solid alkali metal carbonate or bicarbonate by weight of the dosage form;

wherein the dosage form has a crushing strength in the range 6.5-15 Kp and a disintegration time of less than 10 minutes at a compression force above 80 MPa,

provided that the ibuprofen medicament does not contain a calcium salt of ibuprofen in combination with an alkali metal salt of ibuprofen.

F2

Sub G

16. (Amended) A method of obtaining an onset-hastened analgesic and/or anti-pyretic response comprising the oral administration of a non-effervescent compressed solid dosage form comprising 35% or more by weight of a racemic ibuprofen medicament in homogeneous admixture with a carrier material comprising

i) a compressible filler component combined with a disintegrating component, and

ii) 3-20% solid alkali metal carbonate or bicarbonate by weight of the dosage form,

wherein the dosage form has a crushing strength in the range of 6.5-15 Kp and a disintegration time of less than 10 minutes at a compression force above 80 MPa,

provided that the ibuprofen medicament does not include a calcium salt of ibuprofen in combination with an alkali metal salt of ibuprofen.

F3
Sub 3
G3

26. (Amended) A solid formulation having a layer comprising a composition comprising a racemic ibuprofen medicament in homogeneous admixture with a carrier material, the racemic ibuprofen medicament being present to an extent of 35% or more by weight of the composition and the carrier material comprising a compressible filler component combined with a disintegrating component characterised in that the carrier material comprises 3-20% solid alkali metal carbonate or bicarbonate by weight of the dosage form,

wherein the composition is capable of compression to provide a layer having a crushing strength in the range of 6.5-15 Kp and a disintegration time of less than 10 minutes at a compression force above 80 MPa.

REMARKS

Claims 1-10, 16-19, 26, 30 and 31 are pending. By this Amendment, claims 27-29 and 38 are canceled and claims 1, 16 and 26 are amended. No new matter is added. Also attached hereto is a Request for Continued Examination in which it is requested that the May 16, 2002 Amendment After Final Rejection be entered and considered.

35 U.S.C. § 103

Claims 1-10, 16-19, 26-31 and 38 stand rejected under 35 U.S.C. § 103(a) as being obvious over Greyer et al. (U.S. Patent No. 5,386,535). Claims 1-10, 27-31 and